Peanut immunotherapy

详细信息    查看全文

• 作者：Katherine Anagnostou (1)
  Andrew Clark (2)
  
  1. Department of Paediatric Allergy ; Guy鈥檚 and St Thomas鈥?Hospitals NHS Foundation Trust ; Westminster Bridge Road ; London ; UK
  2. Department of Medicine ; University of Cambridge ; Addenbrooke鈥檚 Hospital ; Box 157 ; Cambridge ; CB2 0QQ ; UK
  
• 关键词：Allergy ; Peanut ; Immunotherapy
• 刊名：Clinical and Translational Allergy
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：4
• 期：1
• 全文大小：288 KB
• 参考文献：1. Bock, SA, Mu帽oz-Furlong, A, Sampson, HA (2001) Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 107: pp. 191-193 CrossRef
  2. Hourihane, JO, Aiken, R, Briggs, R, Gudgeon, LA, Grimshaw, KEC, DunnGalvin, A, Roberts, SR (2007) The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol 119: pp. 1197-1202 CrossRef
  3. Pereira, B, Venter, C, Grundy, J, Clayton, CB, Arshad, SH, Dean, T (2005) Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hypersensitivity among teenagers. J Allergy Clin Immunol 116: pp. 884-892 CrossRef
  4. Venter, C, Hasan Arshad, S, Grundy, J, Pereira, B, Bernie Clayton, C, Voigt, K, Higgins, B, Dean, T (2010) Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy 65: pp. 103-108 CrossRef
  5. Sampson, HA, Mendelson, L, Rosen, JP (1992) Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 327: pp. 380-384 CrossRef
  6. Vadas, P, Perelman, B (2003) Presence of undeclared peanut protein in chocolate bars imported from Europe. J Food Prot 66: pp. 1932-1934
  7. Sch盲ppi, GF, Konrad, V, Imhof, D, Etter, R, W眉thrich, B (2001) Hidden peanut allergens detected in various foods: findings and legal measures. Allergy 56: pp. 1216-1220 CrossRef
  8. Avery, NJ, King, RM, Knight, S, Hourihane, JOB (2003) Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol 14: pp. 378-382 CrossRef
  9. Primeau, MN, Kagan, R, Joseph, L, Lim, H, Dufresne, C, Duffy, C, Prhcal, D, Clarke, A (2000) The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. Clin Exp Allergy 30: pp. 1135-1143 CrossRef
  10. Bock, SA, Atkins, F (1989) The natural history of peanut allergy 1. J Allergy Clin Immunol 83: pp. 900-904 CrossRef
  11. Hourihane, JO, Roberts, SA, Warner, JO (1998) Resolution of peanut allergy: case鈥揷ontrol study. BMJ 316: pp. 1271-1275 CrossRef
  12. Skolnick, HS, Conover-Walker, MK, Koerner, CB, Sampson, HA, Burks, W, Wood, RA (2001) The natural history of peanut allergy. J Allergy Clin Immunol 107: pp. 367-374 CrossRef
  13. Ho, MHK, Wong, WHS, Heine, RG, Hosking, CS, Hill, DJ, Allen, KJ (2008) Early clinical predictors of remission of peanut allergy in children. J Allergy Clin Immunol 121: pp. 731-736 CrossRef
  14. Durham, SR, Walker, SM, Varga, EM, Jacobson, MR, O鈥橞rien, F, Noble, W, Till, SJ, Hamid, QA, Nouri-Aria, KT (1999) Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341: pp. 468-475 CrossRef
  15. Calderon M, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. / Cochrane Database Syst Rev 2007, (1):CD001936. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001936.pub2/pdf/standard
  16. Wilson, DR, Lima, MT, Durham, SR (2005) Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60: pp. 4-12 CrossRef
  17. Ross, RN, Nelson, HS, Finegold, I (2000) Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 22: pp. 351-358 CrossRef
  18. Graft, D, Schuberth, K (1987) Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 80: pp. 162-169 CrossRef
  19. Valentine, M, Schuberth, KC, Kagey-Sobotka, A, Graft, DF, Kwiterovich, KA, Szklo, M, Lichtenstein, LM (1990) The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 323: pp. 1601-1603 CrossRef
  20. Golden, D, Kagey-Sobotka, A, Norman, PS, Hamilton, RG, Lichtenstein, LM (2004) Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 351: pp. 668-674 CrossRef
  21. Longo, G, Barbi, E, Berti, I, Meneghetti, R, Pittalis, A, Ronfani, L, Ventura, A (2008) Specific oral tolerance induction in children with very severe cow鈥檚 milk-induced reactions. J Allergy Clin Immunol 121: pp. 343-347 CrossRef
  22. Bro偶ek, JL, Terracciano, L, Hsu, J, Kreis, J, Compalati, E, Santesso, N, Fiocchi, A, Sch眉nemann, HJ (2012) Oral immunotherapy for IgE-mediated cow鈥檚 milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 42: pp. 363-374 CrossRef
  23. Burks, AW, Jones, SM, Wood, RA, Fleischer, DM, Sicherer, SH, Lindblad, RW, Stablein, D, Henning, AK, Vickery, BP, Liu, AH, Scurlock, AM, Shreffler, WG, Plaut, M, Sampson, HA (2012) Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 367: pp. 233-243 CrossRef
  24. Oppenheimer, JJ, Nelson, HS, Bock, SA, Christensen, F, Leung, DY (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90: pp. 256-262 CrossRef
  25. Nelson, HS, Lahr, J, Rule, R, Bock, A, Leung, D (1997) Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99: pp. 744-751 CrossRef
  26. Clark, AT, Islam, S, King, Y, Deighton, J, Anagnostou, K, Ewan, PW (2009) Successful oral tolerance induction in severe peanut allergy. Allergy 64: pp. 1218-1220 CrossRef
  27. Anagnostou, K, Clark, A, King, Y, Islam, S, Deighton, J, Ewan, P (2011) Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 41: pp. 1273-1281 CrossRef
  28. Jones, SM, Pons, L, Roberts, JL, Scurlock, AM, Perry, TT, Kulis, M, Shreffler, WG, Steele, P, Henry, KA, Adair, M, Francis, JM, Durham, S, Vickery, BP, Zhong, X, Burks, AW (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124: pp. 292-300, 300.e1-97 CrossRef
  29. Varshney, P, Jones, SM, Scurlock, AM, Perry, TT, Kemper, A, Steele, P, Hiegel, A, Kamilaris, J, Carlisle, S, Yue, X, Kulis, M, Pons, L, Vickery, B, Burks, W (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127: pp. 654-660 CrossRef
  30. Anagnostou, K, Islam, S, King, Y, Foley, L, Pasea, L, Bond, S, Palmer, C, Deighton, J, Ewan, P, Clark, A (2014) Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 6736: pp. 1-8
  31. Kim, EH, Bird, JA, Kulis, M, Laubach, S, Pons, L, Shreffler, W, Steele, P, Kamilaris, J, Vickery, B, Burks, AW (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127: pp. 640-646.e1 CrossRef
  32. Fleischer, DM, Burks, AW, Vickery, BP, Scurlock, AM, Wood, RA, Jones, SM, Sicherer, SH, Liu, AH, Stablein, D, Henning, AK, Mayer, L, Lindblad, R, Plaut, M, Sampson, H (2014) Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 131: pp. 119-127.e7 CrossRef
  33. Senti, G, von Moos, S, K眉ndig, TM (2014) Epicutaneous immunotherapy for aeroallergen and food allergy. Curr Treat Options Allergy 1: pp. 68-78 CrossRef
  34. Dupont, C, Kalach, N, Soulaines, P, Legou茅-Morillon, S, Piloquet, H, Benhamou, P-H (2010) Cow鈥檚 milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125: pp. 1165-1167 CrossRef
  35. Wood, RA, Sicherer, SH, Burks, AW, Grishin, A, Henning, AK, Lindblad, R, Stablein, D, Sampson, HA (2013) A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 68: pp. 803-808 CrossRef
  36. Leung, DYM, Sampson, HA, Yunginger, JW, Burks, AW, Schneider, LC, Wortel, CH, Davis, FM, Hyun, JD, Shanahan, WR (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348: pp. 986-993 CrossRef
  37. Schneider, LC, Rachid, R, LeBovidge, J, Blood, E, Mittal, M, Umetsu, DT (2013) A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132: pp. 1368-1374 CrossRef
  38. Blumchen, K, Ulbricht, H, Staden, U, Dobberstein, K, Beschorner, J, de Oliveira, LCL, Shreffler, WG, Sampson, HA, Niggemann, B, Wahn, U, Beyer, K (2010) Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 126: pp. 83-91.e1 CrossRef
  39. Vickery, BP, Scurlock, AM, Kulis, M, Steele, PH, Kamilaris, J, Berglund, JP, Burk, C, Hiegel, A, Carlisle, S, Christie, L, Perry, TT, Pesek, RD, Sheikh, S, Virkud, Y, Smith, PB, Shamji, MH, Durham, SR, Jones, SM, Burks, AW (2014) Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol 133: pp. 468-475 CrossRef
  40. Syed, A, Garcia, MA, Lyu, S-C, Bucayu, R, Kohli, A, Ishida, S, Berglund, JP, Tsai, M, Maecker, H, O鈥橰iordan, G, Galli, SJ, Nadeau, KC (2014) Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 133: pp. 500-510 CrossRef
  41. Varshney, P, Jones, SM, Pons, L, Kulis, M, Steele, PH, Kemper, AR, Steele, P, Hiegel, A, Kamilaris, J, Carlisle, S, Yue, X, Kulis, M, Pons, L, Vickery, B, Burks, AW (2009) Oral immunotherapy (OIT) induces clinical tolerance in peanut-allergic children. J Allergy Clin Immunol 123: pp. S174-S174 CrossRef
  42. Nurmatov U, Venderbosch I, Devereux G, Fer S, Sheikh A: Allergen-specific oral immunotherapy for peanut allergy (Review). / Cochrane Database Syst Rev 2012, (9):CD009014. doi:10.1002/14651858.CD009014.pub2
  
• 刊物主题：Allergology; Immunology; Molecular Medicine;
• 出版者：BioMed Central
• ISSN：2045-7022

文摘

Peanut allergy is common and can be a cause of severe, life-threatening reactions. It is rarely outgrown like other food allergies, such as egg and milk. Peanut allergy has a significant effect on the quality of life of sufferers and their families, due to dietary and social restrictions, but mainly stemming from fear of accidental peanut ingestion. The current management consists of strict avoidance, education and provision of emergency medication, but a disease- modifying therapy is needed for peanut allergy. Recent developments involve the use of immunotherapy, which has shown promise as an active form of treatment. Various routes of administration are being investigated, including subcutaneous, oral, sublingual and epicutaneous routes. Other forms of treatment, such as the use of vaccines and anti-IgE molecules, are also under investigation. So far, results from immunotherapy studies have shown good efficacy in achieving desensitisation to peanut with a good safety profile. However, the issue of long-term tolerance has not been fully addressed yet and larger, phase III studies are required to further investigate safety and efficacy. An assessment of cost/benefit ratio is also required prior to implementing this form of treatment. The use of immunotherapy for peanut allergy is not currently recommended for routine clinical use and should not be attempted outside specialist allergy units.